Abstracts tagged "Churg-Strauss syndrome and treatment"

Abstract Number: 1745 • 2018 ACR/ARHP Annual Meeting
Efficacy of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss) Treatments According to the Type of Manifestations Based on Analysis of 376 Patients
Matthias Papo¹, Giacomo Emmi², Franco Schiavon³, Matthieu Groh⁴, Maria-Letizia Urban², Chiara Marvisi⁵, Jean-Emmanuel Kahn⁴, Alberto Sinico⁶, Maxime Samson⁷, Pascal Cohen¹, Xavier Puéchal¹, Luc Mouthon¹, Loïc Guillevin¹, Augusto Vaglio⁵ and Benjamin Terrier⁸, ¹Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ²Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³Operative Unit of Rheumatology, Department of Medicine DIMED, University of Padova, Padova, Italy, ⁴Service de Médecine Interne, Centre de Référence des Syndromes Hyperéosinophiliques-CEREO, Hôpital Foch, Université Versailles–Saint-Quentin-en-Yvelines, Suresnes, France, ⁵Nephrology Unit, Parma University Hospital, Parma, Italy, ⁶UOS di Immunologia Clinica e UOC di Nefrologia, Azienda Ospedaliera San Carlo Borromeo, Milan, Italy, ⁷Department of Internal Medicine and Clinical Immunology, François-Mitterrand Teaching Hospital, University of Bourgogne-Franche-Comté, Dijon, France, ⁸Department of Internal Medicine, Centre de Référence pour les Maladies Auto-immunes Rares, Paris, France, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) (Churg–Strauss) is a small-vessel necrotizing vasculitis characterized by blood and tissue eosinophilia and asthma. Glucocorticoids (GCs) represent the cornerstone…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].